Top

Cancer Chemotherapy and Pharmacology

Published in:

Open Access 01-10-2014 | Original Article

A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer

Authors: Qiang Zhang, Xiaoli Zhu, Li Zhang, Siqing Sun, Jing Huang, Yong Lin

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2014

Abstract

Purpose

To assess the therapeutic value of biomarker-guided chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Methods

Eighty-five NSCLC patients at stage IIIb or IV were divided into two groups based on the feasibility of biomarker analysis. Group A included patients with biomarker data (n = 41); Group B were patients without biomarker results (n = 44). Tumor samples obtained by fiberoptic bronchoscopy and computerized tomography-guided needle biopsy were analyzed by immunohistochemistry for intratumoral level of excision repair cross-complementing gene 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and β-tubulin III. Chemotherapy regimens in Group A were determined according to the status of molecular signatures, whereas a standard gemcitabine plus cisplatin regimen was used for Group B. Tumor response, patient survival, and adverse effects were monitored for both groups.

Results

The overall response rate, defined as complete response plus partial response, was 56.1 % for Group A, significantly higher than that in Group B (31.8 %; P = 0.024). The median progression-free survival (PFS) time was 5.2 months for Group A, significantly longer than that of Group B (4.1 months; P = 0.026). The 1-year survival rate of Group A was 65.9 %, significantly higher than that of Group B (40.9 %; P = 0.021), whereas the median overall survival times were 13.5 versus 12.5 months for Groups A and B, respectively (P = 0.483). The adverse effects in the two groups were essentially the same.

Conclusions

Biomarker-tailored chemotherapy based on ERCC1, RRM1, and β-tubulin III expression showed significantly increased response rate, median PFS time, and 1-year survival rate in patients with NSCLC.

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef

Rinaldi M, Cauchi C, Gridelli C (2006) First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 17:v64–v67PubMedCrossRef

Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R, CISCA (CISplatin versus CArboplatin) Meta-analysis Group (2007) Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847–857PubMedCrossRef

Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRef

Sarries C, Haura EB, Roig B, Taron M, Abad A, Scagliotti G, Rosell R (2002) Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 3:763–780PubMedCrossRef

Gridelli C, Ardizzoni A, Douillard JY, Hanna N, Manegold C, Perrone F, Pirker R, Rosell R, Shepherd FA, De Petris L, Di Maio M, de Marinis F (2010) Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer 68:319–331PubMedCrossRef

Fisher LA, Bessho M, Bessho T (2008) Processing of a psoralen DNA interstrand cross-link by XPF–ERCC1 complex in vitro. J Biol Chem 283:1275–1281PubMedCrossRef

Simon GR, Ismail-Khan R, Bepler G (2007) Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39:1318–1328PubMedCrossRefPubMedCentral

Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59:9–17PubMedCrossRef

10.

Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355:983–991PubMedCrossRef

11.

Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R (2007) Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25:2747–2754PubMedCrossRef

12.

Roth JA, Carlson JJ (2011) Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 12:393–401PubMedCrossRefPubMedCentral

13.

Gao Z, Han B, Shen J, Gu A, Qi D, Huang J, Shi C, Xiong L, Zhao Y, Jiang L (2011) ERCC1 protein as a guide for individualized therapy of late-stage advanced non-small cell lung cancer. Exp Ther Med 2:811–815PubMedPubMedCentral

14.

Kim SO, Jeong JY, Kim MR, Cho HJ, Ju JY, Kwon YS, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC (2008) Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res 14:3083–3088PubMedCrossRef

15.

Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G (2006) RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:4731–4737PubMedCrossRef

16.

Gong W, Zhang X, Wu J, Chen L, Li L, Sun J, Lv Y, Wei X, Du Y, Jin H, Dong J (2011) RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. Lung Cancer 75:374–380PubMedCrossRef

17.

Dumontet C, Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790–803PubMedCrossRefPubMedCentral

18.

Sève P, Dumontet C (2008) Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 9:168–175PubMedCrossRef

19.

Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M (2005) Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92:E25–E30PubMed

20.

Sève P, Reiman T, Lai R, Hanson J, Santos C, Johnson L, Dabbagh L, Sawyer M, Dumontet C, Mackey JR (2007) Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol 60:27–34PubMedCrossRef

21.

Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Ono A, Naito T, Tsuya A, Nakamura Y, Endo M, Kondo H, Nakajima T, Yamamoto N (2013) The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy. Int J Clin Oncol 18:371–379PubMedCrossRef

22.

Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM, Zhou XW (2012) Association between class III β-tubulin expression and response to paclitaxel/vinorelbine-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer 77:9–15PubMedCrossRef

23.

Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y, Onaya H, Endo M, Sone M, Arai Y (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009(45):228–247

24.

Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Hong WK (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44–53PubMedCrossRef

25.

Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, Fitzgerald P, Aristides M, Schiller JH (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80PubMedCrossRef

26.

Bepler G, Williams C, Schell MJ, Chen W, Zheng Z, Simon G, Fischer JR (2013) Randomized international phase III Trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 31(19):2404–2412PubMedCrossRefPubMedCentral

27.

McCabe A, Dolled-Filhart M, Camp RL, Rimm DL (2005) Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 97:1808–1815PubMedCrossRef

28.

Zalcman G, Bergot E, Creveuil C, Levallet G, Lechapt E (2011) Integrating biomarkers into clinical trials: methodological issues for a new paradigm in non-small cell lung cancer. Curr Opin Oncol 23:106–111PubMedCrossRef

29.

Friboulet L, Olaussen KA, Pignon JP, Shepherd FA, Tsao MS, Graziano S, Soria JC (2013) ERCC1 isoform expression and DNA repair in non–small-cell lung cancer. N Engl J Med 368(12):1101–1110PubMedCrossRefPubMedCentral

30.

Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, et al (2014) Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer 83(2):182–188PubMedCrossRef

31.

Hayden JA, Côté P, Bombardier C (2006) Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 144:427–437PubMedCrossRef

32.

Baty F, Facompré M, Kaiser S, Schumacher M, Pless M, Bubendorf L, Savic S, Marrer E, Budach W, Buess M, Kehren J, Tamm M, Brutsche MH (2010) Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. Am J Respir Crit Care Med 181:181–188PubMedCrossRef

33.

Suwinski R, Klusek A, Tyszkiewicz T, Kowalska M, Szczesniak-Klusek B, Gawkowska-Suwinska M, Tukiendorf A, Kozielski J, Jarzab M (2012) Gene expression from bronchoscopy obtained tumour samples as a predictor of outcome in advanced inoperable lung cancer. PLoS One 7:e41379. doi:10.1371/journal.pone.0041379 PubMedCrossRefPubMedCentral

Title: A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer
Authors: Qiang Zhang
Xiaoli Zhu
Li Zhang
Siqing Sun
Jing Huang
Yong Lin
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2513-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2014

First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901

Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors

Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network

Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies

Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer